vaccines

News
GSK scientist with test tube

GSK raises forecasts for 2024, but shares slide

GSK posted a healthy 13% increase in second-quarter sales this morning and raised its forecasts for the year on the back of gains for its cancer and HIV drugs, beating market expectations.

News
CureVac

GSK goes all-in on CureVac’s mRNA vaccines

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and